Delays in cancer registry reporting may have skewed the findings of the NordICC trial, which evaluated the long-term impact of screening colonoscopies. The trial, involving over 85,000 adults, excluded 221 participants with pre-existing colorectal cancer (CRC) that hadn’t yet appeared in registries—raising questions about the accuracy of reported outcomes. Researchers estimate that 2-3 year delays may have masked the true effectiveness of colonoscopies, showing a lower impact on CRC prevention than reality. If registration had been timely, risk reductions and outcomes could have been significantly better, suggesting a need for deeper investigation. What else might this delay reveal about the real power of colonoscopies?
Trending
- 43% Lower Mortality Seen in Colorectal Screening Participants (HCP Live)
- BioNTech halts mRNA colorectal cancer vaccine trial after safety review (Reuters)
- Microdroplets may reduce colorectal tumor growth at potentially lower cost (Medical Xpress)
- What it takes to build a gut-health service line (GI & Hepatology News)
- Weight Down, Steps Down: The GLP-1 Catch (Medscape)
- Pediatric Gastroenterology Faces AI Reality Check (Medscape)
- Ayble Health Joins Amazon’s Health Benefits Connector to expand Virtual GI Care Access to Millions of Americans (PR Newswire)
- Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening (Guardant Health)
